Hostname: page-component-586b7cd67f-r5fsc Total loading time: 0 Render date: 2024-11-27T02:35:04.212Z Has data issue: false hasContentIssue false
  • English
  • Français

The Economics of Antimicrobial Stewardship: The Current State of the Art and Applying the Business Case Model

Published online by Cambridge University Press:  02 January 2015

Kurt B. Stevenson ,
Joan-Miquel Balada-Llasat ,
Karri Bauer ,
Meredith Deutscher ,
Debra Goff ,
Mark Lustberg ,
Preeti Pancholi ,
Erica Reed ,
David Smeenk  and
Jeremy Taylor
...Show all authors
Kurt B. Stevenson*
Affiliation:
Division of Infectious Diseases, Department of Internal Medicine, College of Medicine, Ohio State University, Columbus, Ohio Department of Clinical Epidemiology, Ohio State University Medical Center, Ohio State University, Columbus, Ohio Division of Epidemiology, College of Public Health, Ohio State University, Columbus, Ohio
Joan-Miquel Balada-Llasat
Affiliation:
Clinical Microbiology, Department of Pathology, College of Medicine, Ohio State University, Columbus, Ohio
Karri Bauer
Affiliation:
Department of Pharmacy, Ohio State University Medical Center, Ohio State University, Columbus, Ohio
Meredith Deutscher
Affiliation:
Division of Infectious Diseases, Department of Internal Medicine, College of Medicine, Ohio State University, Columbus, Ohio Department of Clinical Epidemiology, Ohio State University Medical Center, Ohio State University, Columbus, Ohio
Debra Goff
Affiliation:
Department of Pharmacy, Ohio State University Medical Center, Ohio State University, Columbus, Ohio
Mark Lustberg
Affiliation:
Division of Infectious Diseases, Department of Internal Medicine, College of Medicine, Ohio State University, Columbus, Ohio Department of Clinical Epidemiology, Ohio State University Medical Center, Ohio State University, Columbus, Ohio
Preeti Pancholi
Affiliation:
Clinical Microbiology, Department of Pathology, College of Medicine, Ohio State University, Columbus, Ohio
Erica Reed
Affiliation:
Department of Pharmacy, Ohio State University Medical Center, Ohio State University, Columbus, Ohio
David Smeenk
Affiliation:
Department of Pharmacy, Ohio State University Medical Center, Ohio State University, Columbus, Ohio
Jeremy Taylor
Affiliation:
Department of Pharmacy, Ohio State University Medical Center, Ohio State University, Columbus, Ohio
Jessica West
Affiliation:
Division of Infectious Diseases, Department of Internal Medicine, College of Medicine, Ohio State University, Columbus, Ohio
*
Division of Infectious Diseases, Department of Internal Medicine, College of Medicine, Ohio State University, NI122 Doan Hall, 410 West 10th Avenue, Columbus, Ohio 43210 ([email protected])
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Commentary
Information
Infection Control & Hospital Epidemiology , Volume 33 , Issue 4: Special Topic Issue: Antimicrobial Stewardship , April 2012 , pp. 389 - 397
Copyright
Copyright © The Society for Healthcare Epidemiology of America 2012

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Hayashi, Y, Paterson, DL. Strategies for reduction in duration of antibiotic use in hospitalized patients. Clin Infect Dis 2011;52:1232–1240.Google Scholar
2. Goldmann, DA, Weinstein, RA, Wenzel, RP, et al. Strategies to prevent and control the emergence and spread of antimicrobial-resistant microorganisms in hospitals: a challenge to hospital leadership. JAMA 1996;275:234–240.Google Scholar
3. Goldmann, DA, Huskins, WC. Control of nosocomial antimicrobial-resistant bacteria: a strategic priority for hospitals worldwide. Clin Infect Dis 1997;24(suppl):S139–S145.Google Scholar
4. Shlaes, DM, Gerding, DN, John, JF Jr, et al. Society for Healthcare Epidemiology and Infectious Diseases Society of America joint committee on the prevention of antimicrobial resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Clin Infect Dis 1997;25:584–599.Google Scholar
5. Riebet, HM, Mohammed, J, McDonald, LC, Jarvis, WR. Building communication networks: international network for the study and prevention of emerging antimicrobial resistance. Emerg Infect Dis 2001;7:319–322.Google Scholar
6. Dellit, TH, Owens, RC, McGowan, JE Jr., et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007;44:159–177.Google Scholar
7. McGowan, JE Jr. Antimicrobial resistance in hospital organisms and its relation to antibiotic use. Rev Infect Dis 1983;5:1033.Google Scholar
8. Courcol, RJ, Pinkas, M, Martin, GR. A seven year survey of antibiotic susceptibility and its relationship with usage. J Anti-microb Chemother 1989;23:441–451.Google Scholar
9. Chow, JW, Fine, MJ, Shlaes, DM, et al. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med 1991;115:585–590.Google Scholar
10. Conus, P, Francioli, P. Relationship between ceftriaxone use and resistance of Enterobacter species. J Clin Pharm Ther 1992; 17:303–305.Google Scholar
11. Seppala, H, Klaukka, T, Vuopio-Varkila, J, et al. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. Finnish Study Group for Antimicrobial Resistance. N Engl J Med 1997; 337:441–446.Google Scholar
12. Rahal, JJ, Urban, C, Horn, D, et al. Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella . JAMA 1998;280:1233–1237.Google Scholar
13. Neuhauser, MM, Weinstein, RA, Rydman, R, Danziger, LH, Karam, G, Quinn, JP. Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA 2003;289:885–888.Google Scholar
14. Muller, AA, Mauny, F, Bertin, M, et al. Relationship between spread of methicillin-resistant Staphylococcus aureus and antimicrobial use in a French university hospital. Clin Infect Dis 2003;36:971–978.CrossRefGoogle Scholar
15. Polk, RE, Johnson, CK, McClish, D, Wenzel, RP, Edmond, MB. Predicting hospital rates of fluoroquinolone-resistant Pseudomonas aeruginosa from fluoroquinolone use in US hospitals and their surrounding communities. Clin Infect Dis 2004;39:497–503.Google Scholar
16. Paterson, DL, Ko, WC, Von, GA, et al. International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum beta-lactamase production in nosocomial infections. Ann Intern Med 2004;140:26–32.Google Scholar
17. Marr, JJ, Moffet, HL, Kunin, CM. Guidelines for improving the use of antimicrobial agents in hospitals: a statement by the Infectious Diseases Society of America. J Infect Dis 1988;157:869–876.Google Scholar
18. Schentag, JJ, Ballow, CH, Fritz, AL, et al. Changes in antimicrobial agent usage resulting from interactions among clinical pharmacy, the infectious disease division, and the microbiology laboratory. Diagn Microbiol Infect Dis 1993;16:255–264.CrossRefGoogle ScholarPubMed
19. Carling, P, Fung, T, Killion, A, Terrin, N, Barza, M. Favorable impact of a multidisciplinary antibiotic management program conducted during 7 years. Infect Control Hosp Epidemiol 2003; 24:699–706.Google Scholar
20. LaRocco, A Jr. Concurrent antibiotic review programs: a role for infectious diseases specialists at small community hospitals. Clin Infect Dis 2003;37:742–743.Google Scholar
21. Ansari, F, Gray, K, Nathwani, D, et al. Outcomes of an intervention to improve hospital antibiotic prescribing: interrupted time series with segmented regression analysis. J Antimicrob Chemother 2003;52:842–848.Google Scholar
22. Ruttimann, S, Keck, B, Hartmeier, C, Maetzel, A, Bucher, HC. Long-term antibiotic cost savings from a comprehensive intervention program in a medical department of a university-affiliated teaching hospital. Clin Infect Dis 2004;38:348–356.Google Scholar
23. Lutters, M, Harbarth, S, Janssens, JP, et al. Effect of a comprehensive, multidisciplinary, educational program on the use of antibiotics in a geriatric university hospital. J Am Geriatr Soc 2004;52:112–116.Google Scholar
24. John, JF Jr, Fishman, NO. Programmatic role of the infectious diseases physician in controlling antimicrobial costs in the hospital. Clin Infect Dis 1997;24:471–485.Google Scholar
25. Perencevich, EN, Stone, PW, Wright, SB, Carmeli, Y, Fisman, DN, Cosgrove, SE. Raising standards while watching the bottom line: making a business case for infection control. Infect Control Hosp Epidemiol 2007;28:1121–1133.Google Scholar
26. Stone, PW. Methods for conducting and reporting cost-effectiveness analysis in nursing. Image J Nurs Sch 1998;30:229–234.Google Scholar
27. Lipworth, AD, Hyle, EP, Fishman, NO, et al. Limiting the emergence of extended-spectrum β-lactamase-producing enterobac-teriaceae: influence of patient population characteristics on the response to antimicrobial formulary interventions. Infect Control Hosp Epidemiol 2006;27:279–286.Google Scholar
28. Fishman, N. Antimicrobial stewardship. Am J Med 2006;119: S53–S61.Google Scholar
29. Valiquette, L, Cossette, B, Garant, MP, Diab, H, Pepin, J. Impact of a reduction in the use of high-risk antibiotics on the course of an epidemic of Clostridium dibicüe-associated disease caused by the hypervirulent NAP1/027 strain. Clin Infect Dis 2007; 45(suppl 2):S112–S121.Google Scholar
30. Ohl, CA, Luther, VP. Antimicrobial stewardship for inpatient facilities. J Hosp Med 2011;6(suppl 1):S4–S15.Google Scholar
31. Slain, D, Sarwari, AR, Petros, KO, et al. Impact of a multimodal antimicrobial stewardship program on Pseudomonas aeruginosa susceptibility and antimicrobial use in the intensive care unit setting. Crit Care Res Pract 2011;2011:416–426.Google Scholar
32. Eddy, DM. A Manual for Assessing Health Practices and Designing Health Policies. Philadelphia: The American College of Physicians, 1992.Google Scholar
33. Stone, PW, Schackman, BR, Neukermans, CP, et al. A synthesis of cost-utility analysis literature in infectious disease. Lancet Infect Dis 2005;5:383–391.Google Scholar
34. Stone, PW. Return-on-investment models. Appi Nurs Res 2005; 18:186–189.Google Scholar
35. Zilberberg, MD, Shorr, AF. Understanding cost-effectiveness. Clin Microbiol Infect 2010;16:1707–1712.Google Scholar
36. Sassi, F. Calculating QALYs, comparing QALY and DALY calculations. Health Policy Phn 2006;21:402–408.CrossRefGoogle ScholarPubMed
37. Scheetz, MH, Bolon, MK, Postelnick, M, Noskin, GA, Lee, TA. Cost-effectiveness analysis of an antimicrobial stewardship team on bloodstream infections: a probabilistic analysis. J Antimicrob Chemother 2009;63:816–825.Google Scholar
38. Stone, PW, Braccia, D, Larson, E. Systematic review of economic analyses of health care-associated infections. Am J Infect Control 2005;33:501–509.Google Scholar
39. Neumann, PJ, Greenberg, D, Olchanski, NV, Stóne, PW, Rosen, AB. Growth and quality of the cost-utility literature, 1976-2001. Value Health 2005;8:3–9.CrossRefGoogle ScholarPubMed
40. Russell, LB, Gold, MR, Siegel, JE, Daniels, N, Weinstein, MC. The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine. JAMA 1996;276:1172–1177.Google Scholar
41. Gold, MR, Siegel, JE, Russell, LB, and Weinstein, MC, eds. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press, 1996.Google Scholar
42. Siegel, JE, Weinstein, MC, Russell, LB, Gold, MR. Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. JAMA 1996;276:1339–1341.Google Scholar
43. Weinstein, MC, Siegel, JE, Gold, MR, Kamlet, MS, Russell, LB. Recommendations of the Panel on Cost-Effectiveness in Health and Medicine. JAMA 1996;276:1253–1258.Google Scholar
44. Ward, WJ Jr, Spragens, L, Smithson, K. Building the business case for clinical quality. Healthc Einanc Manage 2006;60:92–98.Google Scholar
45. Roberts, RR, Frutos, PW, Ciavarella, GG, et al. Distribution of variable vs fixed costs of hospital care. JAMA 1999;281:644–649.Google Scholar
46. Graves, N. Economics and preventing hospital-acquired infection. Emerg Infect Dis 2004;10:561–566.Google Scholar
47. Stone, PW. Economic burden of healthcare-associated infections: an American perspective. Expert Rev Pharmacoecon Outcomes Res 2009;9:417–422.Google Scholar
48. Eber, MR, Laxminarayan, R, Perencevich, EN, Malani, A. Clinical and economic outcomes attributable to health care-associated sepsis and pneumonia. Arch Intern Med 2010;170:347–353.Google Scholar
49. Engemann, JJ, Carmeli, Y, Cosgrove, SE, et al. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin Infect Dis 2003;36:592–598.Google Scholar
50. Cosgrove, SE, Qi, Y, Kaye, KS, Harbarth, S, Karchmer, AW, Carmeli, Y. The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges. Infect Control Hosp Epidemiol 2005;26:166–174.Google Scholar
51. Bauer, KA, West, JE, Balada-Llasat, JM, Pancholi, P, Stevenson, KB, Goff, DA. An antimicrobial stewardship program's impact with rapid polymerase chain reaction methicillin-resistant Staphylococcus aureus/S. aureus blood culture test in patients with S. aureus bacteremia. Clin Infect Dis 2010;51:1074–1080.Google Scholar
52. Kamai, J, Rogers, P, Saltz, J, Mekhjian, H. Information warehouse as a tool to analyze computerized physician order entry order set utilization: opportunities for improvement. AMIA Annu Symp Proc 2003:336–340.Google Scholar
53. Schwartz, DN, Evans, RS, Camins, C, et al. Deriving measures of intensive care unit antimicrobial use from computerized pharmacy data: methods, validation, and overcoming barriers. Infect Control Hosp Epidemiol 2011;32:472–480.Google Scholar
54. Lodise, TP Jr, Lomaestro, B, Drusano, GL. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis 2007;44:357–363.Google Scholar